DiscoverBlood & CancerGrands rounds in the age of COVID-19; cardiotoxicity in breast cancer
Grands rounds in the age of COVID-19; cardiotoxicity in breast cancer

Grands rounds in the age of COVID-19; cardiotoxicity in breast cancer

Update: 2020-03-26
Share

Description

Susan Dent, MD, codirector of the cardio-oncology program at Duke University in Durham, N.C., reflects on virtual grand rounds, telehealth, the screening of patients before clinic visits, and other new realities of cancer care in the age of COVID-19. Dr. Dent also discusses the importance of assessing breast cancer patients for cardiotoxicity.

In Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, talks about the importance of advance directives.

*  *  *  

Cardiotoxicity in breast cancer treatment

HER2 drugs (such as trastuzumab) and conjugates

  • If given appropriately, these drugs have limited cardiotoxicity.
  • The mechanism of cardiotoxicity is a “stunning of the heart.”
  • If there is a significant drop in left ventricular ejection fraction, hold the drug.
  • When problems arise, they tend to occur early on.
  • Important to assess baseline risk factors. Older individuals with underlying hypertension, diabetes, and other conditions need monitoring.

Anthracyclines

  • The appropriate/safe dose of anthracyclines may be different for each person, based on risk factors such as age and underlying conditions.
  • Assess patients at baseline using cardiac imaging and biomarkers, and risk factors. If no symptoms of cardiotoxicity, reassess 6-12 months after treatment.
  • If a patient has poorly controlled hypertension or diabetes, those factors should be better managed to minimize the risk from anthracyclines.

Liposomal anthracyclines

  • These formulations are less cardiotoxic, but they have not been widely adopted in breast cancer.

Immuno-oncology antibodies

  • Myocarditis is one of many side effects seen with immunotherapy. It’s not a common side effect (about 1% or less), but when it does occur, it has a 50% fatality rate. Have a high level of suspicion for myocarditis if a patient on immunotherapy presents with shortness of breath and chest pain.

*   *   *  

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Grands rounds in the age of COVID-19; cardiotoxicity in breast cancer

Grands rounds in the age of COVID-19; cardiotoxicity in breast cancer

MDedge Hematology Oncology